We are live on
!
Find out more
GTC
Ghost Tree Capital Portfolio holdings
AUM
$331M
1-Year Est. Return
70.11%
This Fund
S&P 500
This Quarter
Est. Return
+8.97%
1 Year Est. Return
+70.11%
3 Year Est. Return
+265.05%
5 Year Est. Return
+3,034.98%
10 Year Est. Return
+22,104.75%
AUM
$425M
AUM Growth
-$23.3M
(-5.2%)
Cap. Flow
+$28.2M
Cap. Flow
% of AUM
6.64%
Top 10 Holdings %
Top 10 Hldgs %
49.03%
Holding
60
New
17
Increased
11
Reduced
11
Closed
10
Top Buys
| 1 |
Kura Oncology
KURA
|
+$8.7M |
| 2 |
iShares Russell 2000 ETF
IWM
|
+$6.55M |
| 3 |
Gyre Therapeutics
GYRE
|
+$6.09M |
| 4 |
Celldex Therapeutics
CLDX
|
+$5.74M |
| 5 |
Viridian Therapeutics
VRDN
|
+$5.62M |
Top Sells
| 1 |
Travere Therapeutics
TVTX
|
+$12.9M |
| 2 |
CNST
Constellation Pharmaceuticals, Inc.
CNST
|
+$10.6M |
| 3 |
Rocket Pharmaceuticals
RCKT
|
+$9.61M |
| 4 |
SURF
Surface Oncology, Inc. Common Stock
SURF
|
+$9.24M |
| 5 |
FPRX
Five Prime Therapeutics, Inc.
FPRX
|
+$8.51M |
Sector Composition
| 1 | Healthcare | 77.39% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
PUT
Invesco QQQ Trust
QQQ
$466B
| $47.9M | 11.25% |
150,000
+50,000
| +50% | +$16M |
|
2
Syndax Pharmaceuticals
SNDX
$2.02B
| $26.3M | 6.18% |
1,175,000
-175,000
| -13% | -$3.95M |
|
|
TRIL
3
DELISTED
Trillium Therapeutics Inc.
TRIL
| $20.9M | 4.92% |
1,950,000
| – | – |
|
4
PUT
ARK Genomic Revolution ETF
ARKG
$1.61B
| $17.7M | 4.17% |
+200,000
| New | +$19.8M |
|
5
Ascendis Pharma A/S
ASND
$17.1B
| $17.4M | 4.09% |
135,000
+30,000
| +29% | +$4.56M |
|
|
6
Kura Oncology
KURA
$964M
| $17M | 3.99% |
600,000
+275,000
| +85% | +$8.7M |
|
7
Iovance Biotherapeutics
IOVA
$2.23B
| $15.8M | 3.72% |
500,000
| – | – |
|
8
Fate Therapeutics
FATE
$324M
| $15.3M | 3.58% |
185,000
+20,000
| +12% | +$1.92M |
|
9
Xenon Pharmaceuticals
XENE
$6.6B
| $15.2M | 3.58% |
850,000
+150,000
| +21% | +$2.54M |
|
10
Aclaris Therapeutics
ACRS
$793M
| $15.1M | 3.55% |
600,000
-50,000
| -8% | -$978K |
|
|
11
Rocket Pharmaceuticals
RCKT
$376M
| $14.4M | 3.39% |
325,000
-175,000
| -35% | -$9.61M |
|
12
Cogent Biosciences
COGT
$6.68B
| $14M | 3.3% |
1,600,000
+500,000
| +45% | +$4.81M |
|
13
Arvinas
ARVN
$517M
| $13.6M | 3.18% |
205,000
| – | – |
|
|
APLS
14
DELISTED
Apellis Pharmaceuticals
APLS
| $9.65M | 2.27% |
225,000
-100,000
| -31% | -$4.73M |
|
15
TG Therapeutics
TGTX
$8.4B
| $9.64M | 2.27% |
200,000
-50,000
| -20% | -$2.4M |
|
16
VistaGen Therapeutics
VTGN
$9.4M
| $8.83M | 2.07% |
138,123
+56,790
| +70% | +$3.79M |
|
|
MRTX
17
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $8.56M | 2.01% |
50,000
| – | – |
|
|
VRNA
18
DELISTED
Verona Pharma
VRNA
| $7.85M | 1.85% |
939,043
+129,043
| +16% | +$1.07M |
|
19
Aldeyra Therapeutics
ALDX
$102M
| $7.72M | 1.81% |
650,000
| – | – |
|
|
MRSN
20
DELISTED
Mersana Therapeutics
MRSN
| $7.28M | 1.71% |
18,000
-6,000
| -25% | -$2.91M |
|
|
ISEE
21
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $6.95M | 1.63% |
1,125,000
-250,000
| -18% | -$1.52M |
|
|
22
iShares Russell 2000 ETF
IWM
$82.2B
| $6.63M | 1.56% |
+30,000
| New | +$6.55M |
|
|
CNST
23
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
| $6.43M | 1.51% |
275,000
-350,000
| -56% | -$10.6M |
|
24
Biogen
BIIB
$30.4B
| $5.59M | 1.32% |
20,000
+17,800
| +809% | +$4.8M |
|
|
25
Celldex Therapeutics
CLDX
$2.77B
| $5.15M | 1.21% |
+250,000
| New | +$5.74M |
|
Similar funds
SF
AFS
SFA
E
OHCM
MC
BRA
S
Ghost Tree Capital's Q1 2021 Portfolio in Review
As of Q1 2021, Ghost Tree Capital held 60 positions worth $425M, down 5.2% from $449M the previous quarter. Its ten largest holdings account for 49% of the portfolio.
Ghost Tree Capital deployed $28.2M of net new capital in Q1 2021, opening 17 new positions and adding to 11 existing holdings. Its largest new stake was iShares Russell 2000 ETF: 30,000 shares worth $6.63M.
By sector, the portfolio is most concentrated in Healthcare at 77% of assets, down from 83% a quarter earlier.
On the sell side, the largest reduction was Constellation Pharmaceuticals, Inc., an estimated $10.6M trimmed.
- Ghost Tree Capital's largest Q1 2021 buy was iShares Russell 2000 ETF: 30,000 shares worth $6.63M.
- Ghost Tree Capital added most to Kura Oncology in Q1 2021, an estimated $8.7M increase.
- Ghost Tree Capital's biggest Q1 2021 reduction was Constellation Pharmaceuticals, Inc., cutting an estimated $10.6M.
- Ghost Tree Capital fully exited Travere Therapeutics in Q1 2021, selling an estimated $12.9M.
- Ghost Tree Capital's ten largest holdings make up 49% of its $425M portfolio in Q1 2021.
- Ghost Tree Capital opened 17 new positions and closed 10 in Q1 2021.
- Ghost Tree Capital's portfolio value fell 5.2% quarter-over-quarter to $425M.
Based on Ghost Tree Capital's 13F filing for Q1 2021, filed 14 May 2021.